Harbor Medical Clinic and Wellness Center
- PRP Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
- Red Light Therapy
Sacramento, CA
Sacramento anchors the state capital region and sits at the junction of Central Valley agriculture and Sierra Nevada mining history. Local chelation demand has a distinct regional signature, agricultural arsenic exposure from Valley well water, legacy mercury deposits in Sierra rivers from 19th century gold mining, and lead in older Midtown and East Sacramento housing. The California Department of Public Health maintains the Mercury in Fish and Mining Areas guidance that local integrative providers often reference during intake.
4 Sacramento clinics in this directory offer chelation therapy, drawing on California-licensed MDs, DOs, and naturopathic doctors working within their A2Z integrative scope. Common agents include calcium disodium EDTA, DMPS, DMSA, and deferoxamine, matched to the metal confirmed on provocation or baseline testing. Protocols span 10-session detox courses and longer 30-session cardiovascular series modeled on the TACT trial. Pricing is almost entirely cash-pay, with UC Davis Health providing backup hospital-based chelation for confirmed poisoning cases. Regenerated.com does not recommend chelation for autism or cardiovascular disease outside clinical trials, and emphasizes that off-label chelation has caused fatal hypocalcemia.
Regulatory context
The FDA has approved a narrow set of chelating agents for specific heavy metal toxicities. Calcium disodium edetate (CaNa2EDTA, Versenate) is approved for symptomatic lead poisoning, succimer (Chemet, DMSA) for pediatric lead poisoning at blood lead levels above 45 mcg/dL, deferoxamine (Desferal) and deferasirox (Exjade) for chronic iron overload, and dimercaprol (BAL) for arsenic, gold, and acute lead poisoning. Use of EDTA chelation for cardiovascular disease was studied in the NIH-funded TACT trial (2013) with controversial findings and remains not FDA-approved for that indication. Chelation for autism spectrum disorder is not evidence-based and has been linked to pediatric deaths. The FDA issued a 2010 sweep of warning letters to compounders marketing OTC chelation products with unapproved disease claims.
The Medical Board of California has disciplined physicians for marketing chelation as a treatment for autism, atherosclerosis, and Alzheimer's disease without adequate informed consent or evidence base. California Department of Public Health has investigated clinics for unsanitary IV practices. The Pittsburgh 2005 pediatric autism chelation death prompted California medical board guidance reinforcing that the wrong EDTA salt (Na2EDTA versus CaNa2EDTA) can be fatal. Compounded DMPS distribution has drawn scrutiny under California pharmacy law.